Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean

Oruka Therapeutics' Senior Vice President of Finance Arjun Agarwal sold 9,854 shares worth approximately $687,000 in mid-June 2026, reducing his direct holdings by 36.83%. The sale occurred after the stock had already surged 450% over the previous year and two weeks before it reached nearly 700% gains. The insider sale follows positive Phase 2 clinical data for the company's monoclonal antibody therapies ORKA-001 and ORKA-002, though the company continues to operate at a net loss with quarterly losses widening to $31.8 million.